Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS
Not Applicable
- Conditions
- COVID-19 Disease.COVID-19 DiseaseU07.02
- Registration Number
- IRCT20200409047007N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Po2 / FIO2 ratio less than 300 despite receiving standard treatment
The patient should be between 18 and 75 years old
Normal IgA level
Less than a week has passed since the patient entered the IC
Exclusion Criteria
Uncontrolled HTN
Advanced heart failure
Systolic blood pressure less than 90 mm Hg
COPD
The patient is intubated
Chronic renal failure with GFR less than 30
Advanced hepatic failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality rate in 4 weeks from the time of entry into the study. Timepoint: The first month of entering the study. Method of measurement: Continuous clinical evaluation.
- Secondary Outcome Measures
Name Time Method The length of hospital stay in the ICU from the time of entering the study. Timepoint: Daily evaluation. Method of measurement: Clinical evaluation.